FindTrial
Sign In

Study on Predicting the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients Using 18F-FAPI PET/CT

Study on Predicting the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients Using 18F-FAPI PET/CT

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600118745
Enrollment
Unknown
Registered
2026-02-10
Start date
2026-03-08
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

Observation group:N/A

Sponsors

General Hospital of the Eastern Theater Command, PLA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients with histologically confirmed advanced or metastatic NSCLC (stage IIIB - IV). (2) Planned to receive first - line immunotherapy as monotherapy or in combination (e.g., anti - PD - 1/PD - L1 monoclonal antibodies). (3) ECOG score of 0 - 1 with an estimated survival of =6 months. (4) Presence of at least one measurable lesion (RECIST 1.1 criteria). (5) Informed consent signed and agreement to participate in follow - up. (6) The subject must be able to remain supine on the scanning table for at least 1 hour.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
FAP positive volume;Objective Response Rate (ORR);—

Secondary

MeasureTime frame
SUVmax;Tumor/Mediastinal Blood Pool Ratio;Tumor/Liver Ratio;Total FAP expression;Progression-Free Survival (PFS) ;Overall Survival (OS);—

Countries

China

Contacts

Public ContactWu Jiang

General Hospital of the Eastern Theater Command, PLA

wudoc@163.com+86 138 1388 4286

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026